Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 1/20 | 0.52 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.52 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.52 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.52 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242034 | 0.84 | SLC18A3 (0.47) | CCR3SLC6A4 | |
| SCHEMBL236849 | 0.78 | DHFR (0.46) | CYP2C9TSHRMAPTGFER | |
| SCHEMBL25031021 | 0.77 | FFAR4 (0.40) | — | |
| SCHEMBL28855647 | 0.77 | FFAR4 (0.38) | — | |
| SCHEMBL25194061 | 0.77 | FFAR4 (0.39) | — | |
| SCHEMBL6429226 | 0.77 | SLC6A2 (0.56) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL6427944 | 0.76 | MEN1 (0.61) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL27098837 | 0.75 | FFAR4 (0.41) | — | |
| SCHEMBL6636349 | 0.74 | CCR3 (0.65) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL240318 | 0.74 | SSTR2 (0.38) | MEN1KMT2AMAPTHTTGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| EP-3438106-A1 | ANTI-VIRAL COMPOUNDS | AbbVie Ireland Unlimited Company (IE) | 2019-02-06 | — | — | EP | disclosed |
| US-20190015402-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10039754-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10028937-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170157105-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157104-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2678334-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2017-03-22 | — | — | EP | disclosed |
| US-9586978-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-2692346-B1 | An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative | ABBVIE BAHAMAS LTD (BS) | 2015-12-02 | — | — | EP | disclosed |
| US-8921514-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2692346-A1 | An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative | Abbvie Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| EP-2692726-A1 | Anti-viral compounds | Abbvie Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| EP-2678334-A1 | ANTI-VIRAL COMPOUNDS | Abbvie Inc. (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-2627651-A1 | ANTI-VIRAL COMPOUNDS | Abbvie Inc. (US) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012116257-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2012-08-30 | — | — | WO | disclosed |
| US-20120220562-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2012051361-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-04-19 | — | — | WO | disclosed |
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110207699-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10028937-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | PRMT3 1926/4885CARM1 3322/4885PRMT6 2312/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | PRMT3 1926/4885CARM1 3322/4885PRMT6 2312/4885 |
| US-20120220562-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | PRMT3 1926/4885CARM1 3322/4885PRMT6 2312/4885 |
| US-20170157105-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | PRMT3 1926/4885CARM1 3322/4885PRMT6 2312/4885 |
| US-20170157104-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | PRMT3 1926/4885CARM1 3322/4885PRMT6 2312/4885 |
| US-20110207699-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | PRMT3 1926/4885CARM1 3322/4885PRMT6 2312/4885 |
| US-20190015402-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | PRMT3 1926/4885CARM1 3322/4885PRMT6 2312/4885 |
| US-20120004196-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | PRMT3 1926/4885CARM1 3322/4885PRMT6 2312/4885 |
| US-10039754-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | PRMT3 1926/4885CARM1 3322/4885PRMT6 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.